TerminatedNot Applicable

Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia

Stopped: poor recruitment

Belgium54 participantsStarted 2017-10-04

Plain-language summary

CALIF study is a monocentric observational study which aim is to analyse the value of adding procalcitonin (PCT, a pre-hormon increased in bacterial infection and septicaemia) in the management of chemo-induced febrile neutropenia occurring in patient with solid tumour. Febrile neutropenia will be managed according to international guidelines. PCT will be dosed at initial presentation. Primary objective is to determine the optimal value of PCT for the detection of septicaemia in low risk (according to MASCC score). The investigators plan also to compare two risk stratification scores: the validated MASCC score and a recently developed score which includes PCT and other more objective items.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * more than 18 years old * Patients with solid malignant tumor treated by chemotherapy (neoadjuvant, concomittant, adjuvant or metastatic) * Febrile neutropenia chemo-induced (fever \> 38°C, neutrophils \< 500 /microliter or nadir \< 500 /microliter) * Patients non hospitalized at the event (when he presented febrile neutropenia) * Informed consent signed Exclusion Criteria: * Thyroid medullar carcinoma * Patient not able to understand protocol (mental retardation, psychiatric disorders, .... )

What they're measuring

Minimum level of ProCalcitonin

Timeframe: at day 0

Trial details

NCT IDNCT03182465

SponsorCliniques universitaires Saint-Luc- Université Catholique de Louvain

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-25